Fig. 4From: A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failureImpact of changes in the annual rate of HK on costs, QALYs and life years (compared to no HK incidence). All other inputs remain as in the base case cost-effectiveness analysisBack to article page